Deborah DeHertogh
About
In The Last Decade
Deborah DeHertogh
21 papers receiving 2.7k citations
Hit Papers
Peers
Comparison fields: 5 of 81
- Epidemiology 2.5k
- Hepatology 2.3k
- Infectious Diseases 337
- Pathology and Forensic Medicine 171
- Dermatology 163
Countries citing papers authored by Deborah DeHertogh
This map shows the geographic impact of Deborah DeHertogh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah DeHertogh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah DeHertogh more than expected).
Fields of papers citing papers by Deborah DeHertogh
This network shows the impact of papers produced by Deborah DeHertogh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah DeHertogh. The network helps show where Deborah DeHertogh may publish in the future.
Co-authorship network of co-authors of Deborah DeHertogh
This figure shows the co-authorship network connecting the top 25 collaborators of Deborah DeHertogh. A scholar is included among the top collaborators of Deborah DeHertogh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah DeHertogh. Deborah DeHertogh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B breakdown → | 900 |
| 2 | A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B breakdown → | 1064 |
| 3 | 4 | |
| 4 | 1 | |
| 5 | 6 | |
| 6 | Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. | 21 |
| 7 | 226 | |
| 8 | 63 | |
| 9 | 124 | |
| 10 | 41 | |
| 11 | 64 | |
| 12 | 14 | |
| 13 | 6 | |
| 14 | 10 | |
| 15 | 2 | |
| 16 | 6 | |
| 17 | 14 | |
| 18 | 14 | |
| 19 | 20 | |
| 20 | 178 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.